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Abstract 
 
Peroxiredoxins (Prx) are the family of antioxidants that efficiently scavenge peroxides. Prxs have 
characteristics that distinguish them from conventional ROS scavenging antioxidants, such as the 
hyper oxidized state in the presence of excess peroxide or the capability to form oligomeric structures. 
These characters affect to the redox sensors that transmit the signals as the cellular response to 
oxidative stress. Prxs are abundantly existed in diverse locations of cellular organelles include the 
cytosol, lysozyme, mitochondria and nucleus, etc. Interestingly, in many cases Prxs in the 
mitochondria of tumors are highly expressed. It seems that the way of overcoming the highly 
expressed ROS generation caused by abnormal cell growth. In addition, the high levels of antioxidant 
proteins assign protection against ROS generations caused by therapeutic treatments. This 
phenomenon tell us that Prx have the potential of anticancer drugs target. The Cyclophilin D (CypD), 
the protein in the mitochondrial matrix and one of the core proteins of mitochondrial permeability 
transition pore (MPTP), are highly expressed in many type of tumors, but the function and 
mechanisms are currently unclear. CypD are also responds to ROS generation in the mitochondria. 
Moreover, I confirmed that the CypD have the binding capacity with mitochondrial Prxs and the 
binding strength is different according to the existence of ROS, in vitro condition. Altogether, these 
results suggest that ROS dependent responses of CypD are related to mitochondrial Prxs. 
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CHAPTER I 
The binding of CypD with mitochondrial Prxs 
 
I-1. Introduction 
 
Apoptosis is genetically programed mechanism that may be connected with several cellular 
signaling pathways. The well-known pathways of apoptosis are intrinsic and extrinsic pathway. Most 
cell death in the case of vertebrate via intrinsic apoptotic pathways are deeply related with 
mitochondria (Kroemer, Galluzzi, & Brenner, 2007). After adequate cell death stimulations are given, 
the mitochondria release cytochrome c (Cyt c), which is located in mitochondrial internal membrane 
space (IMS) (Garrido et al., 2006). As the function of Cyt c in the mitochondria is electron shuttle at 
electron transport chain, the release of Cyt c by mitochondrial permeability transition pore (MPTP) is 
critical role to undergo the cell death. The MPTP pore opening release not only Cyt c but also AIF, 
HtrA2/Omi, SMAC/DIABLO and EndoG involved in cell death signals (Muirhead, Borger, Aitken, 
Conway, & Gunn-Moore, 2010). In healthy cells, the mitochondria internal membrane (IM) is non-
permeable barrier for balancing ions between the matrix and inter membrane space (Chen, 1988). The 
charging imbalance resulting from the electro-chemical gradient is needed to maintain the inner 
mitochondrial trans-membrane potential (ΔΨm) (Crompton, 1999). Therefore, the maintenance of ions 
gradient is important for cell survival and is tightly regulated. If some problems break ΔΨm, MPTP 
pores are opened to re-balance it. 
The MPTP is proposed to consist of several core proteins, the voltage dependent anion channel 
(VDAC), localized on outer membrane (OM), the adenine nucleotide translocase (ANT) in the inner 
membrane (IM) and Cyclophilin D in the matrix (Kokoszka et al., 2004; Nakagawa et al., 2005). 
Some stimulations like calcium overload and ROS generation result in assembling of these proteins 
which allows incoming of the solute from the cytosol and break the membrane potential of 
mitochondria (Duchen, 2000). Interestingly, the inhibition of CypD by cyclosporin A (CsA) inhibit the 
generation of MPTP pore opening. However, the precise mechanism and function of CypD is not well 
known (Baines et al., 2005; Halestrap, Connern, Griffiths, & Kerr, 1997). 
To know how the CypD is regulated, I screened the proteins to find the novel proteins assumed to 
be CypD partner proteins. On the screening, the novel proteins, peroxiredoxin, were searched with 
VDAC, ANT and Hsp90 that are already known as CypD binding proteins. 
Mitochondria are the main energy supplier in cells that generate the energy molecule ATP 
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(Waterhouse et al., 2001). During this process, mitochondria make reactive oxygen species (ROS) 
inevitably. Some cell signaling is regulated by ROS generation but excessive ROS generation is 
harmful to cell (Cadenas & Davies, 2000). Tumors which rapidly grow are hypoxic due to insufficient 
angiogenesis to supply an adequate amount of oxygen. Furthermore, the mutations of genes in the 
tumors affect ROS generation, too. Theses ROS can cause massive cellular damage if they are not 
detoxified by antioxidant system (Cox, Winterbourn, & Hampton, 2010).  
Peroxiredoxin, found when at screening CypD partner proteins, is one of the cellular defense 
mechanism for reducing oxidative stress. Prxs, the family of the hydrogen peroxide scavenger 
proteins are abundant in the diverse locations in the cell (Wood, Schroder, Harris, & Poole, 2003). 
Interestingly, the PrxIII and PrxV which have the mitochondria targeting sequence were screened as 
candidates of CypD partner proteins. In addition, the PrxV are located in peroxisome and the nucleus 
(Cox et al., 2010).  
All Prxs are regulated by oxidizing their Cys groups when they meet hydrogen peroxide. Some 
types of Prx can change their formation according to oxidized levels. Interestingly, diverse oxidized 
status can induce much different type of peptide complex bundles like tetramer, octamer, decamer and 
dodecamer (Knoops, Goemaere, Van der Eecken, & Declercq, 2011). In the case of hyper-oxidized 
status which is hard to return on reduced formation, the sulfiredoxin from cytosol can reduce hyper 
oxidized to reduce it. The numbers of peptides and Cys groups needed to assign their antioxidant 
function are the major criterion for dividing Prxs family (Lowther & Haynes, 2011; Noh, Baek, Jeong, 
Rhee, & Chang, 2009). Especially, Prxs can be divided in three groups: typical 2-Cys Prxs, atypical 2-
Cys Prxs, 1-Cys Prxs. All those Prxs have similar mechanism against their anti-oxidizing activities 
(Chae et al., 1997; Cox et al., 2009; Wood et al., 2003)(Table 1). The one of the two Cys participates 
in anti-oxidizing function and another is involved in reaction of reducing the opponent oxidizing Cys. 
As the 1-Cys Prxs have one peroxidatic Cys, the thiol containg reductants are involved in reducing 
processes. In case of PrxIII and PrxV, they are categorized to typical 2-Cys Prx and atypical 2-Cys Prx 
(Bae, Ahn, Han, & Noh, 2007; Cox et al., 2010; De Simoni, Linard, Hermans, Knoops, & Goemaere, 
2013; Hirota et al., 2010; Kang, Rhee, Chang, Jeong, & Choi, 2005)(Figure1). To reuse the oxidized 
Prx proteins, the electron donor proteins, reductase and electron donor are needed (Figure1-2). As the 
diverse oxidative state can make disulfide bond and various peptide complex bundles (Knoops et al., 
2011), I assumed that the change of their state can influence on binding capacity with other molecules. 
On this hypothesis, I focused on studying ROS dependent regulation of CypD and that this regulation 
may be affected by mitochondrial Prxs.  
As the CypD is well known as anti-cancer drug target, the mitochondrial Prxs which overexpressed 
in hepatocellular carcinoma and breast cancer to get tumorigenic characteristics against ROS are able 
to be chosen as anti-cancer drug target, as well (Baines et al., 2005; Lin & Lechleiter, 2002; 
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Nakagawa et al., 2005). Through these studies, I clarify the binding capacity between CypD and 
mitochondrial Prxs and suggest the model of their mechanism.  
 
I-2. Material & Method 
 
Material & Method 
 
I-2-1. Preparation of recombinant human mitochondrial CypD/PrxIII/V 
 
cDNA synthesis: The total RNA was isolated from MDA-MB-231 using RNA isolation kit (Quiagen). 
The RNA sample was mixed with oligo dT and incubated for 5min at 70°C. The heated sample was 
placed on the ice for 1min and mixed with RNaseOUT, Reverse transcriptase (M-MuLV, New 
England Biolabs), Reaction Mix buffer for 3 hours at 42°C. The inactivation of reaction was at 80°C 
for 5min.  
 
Cloning of CypD, PrxIII/V: The Pfu DNA polymerase (Invitrogen) was used to amplifyng the 
nucleotides of CypD, PrxIII, PrxV. The nucleotides were inserted to pGEX4T1 (GE Healthcare) and 
pET28b (+) (Novagen) vectors. As the three proteins have the mitochondrial targeting sequence, 
recombinant proteins were needed to cut out this sequence. For this reasons the design of forward 
primers were started next to the mitochondrial targeting sequence. The forward primer of CypD was 
5’-AAA AAC ATA TGT GCA GCA AGG GCT CCG GCG A-3’ and the reverse primer was 5’-AAA 
AAA CTC GAG TTA GCT CAA CTG GCC ACA GTC-3’. 5’-AAA AAA CCC GGG ACC TGC TGT 
CAC CCA GCA TGC A-3’ was used as the forward primer and 5’-AAA AAA AAA AGC GGC CGC 
TGA TCT ACT GAT TTA CCT TCT GAA A-3’ was used as the reverse primer for GST tagged PrxIII. 
5’-AAA AAA CCC GGG AAT GGC CCC AAT CAA GGT GGG A-3’ was used as the forward primer 
and 5’-AAA AAA AAA AGC GGC CGC TCA GAG CTG TGA GAT GAT ATT-3’ was used as the 
reverse primer for GST tagged PrxV. The final constructs were transformed into E. coli DH5-alpha 
and BL21/DE3 bacterial cells. 
 
I-2-2. RNA interference 
 
For knockdown of PrxV, small interference RNA (siRNA) duplexes were used. The negative control 
siRNA was 5’ – ACU CUA UCU GCA CGC UGA C – 3’. The siPrxV sequences were as follows: 5’ - 
GAC GUC UCA AGA GGU UCU CUU- 3’; 5’ - GGG UGU GCU GUU UGG AGU UUU - 3’. The 
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H9C2 cell line was plated on 6 well plate about 60% confluence state. The siRNA (40nM) was mixed 
with G-fectin (2ul) (Genolution) in RNAse free PBS (200ul) and incubated for 10min. The mixture 
was treated on the sample cells and incubated for 48hr. 
 
I-2-3. Protein purification 
 
GST tagged protein purification: The CypD and PrxIII/V proteins fused to GST-tag (pGEX-4T-1) 
were overexpressed from Escherichia coli BL21/DE3 cells grown in Luria Broth (LB) medium in 
presence of ampicillin at 36°C. The cell reached OD600 0.4-0.6, the recombinant protein was induced 
by addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.1mM for 
24hours at 18°C. The bacterial cell was harvested by centrifugation at 3,500rpm for 15min at 4°C. 
The harvested cell was resuspended in lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 5mM 
MgCl2) with final concentration of 1mM DTT or 5mM β-mercaptoethanol. The resuspended bacteria 
sample in the ice was burst using ultra-sonicator. The lysis sample was centrifuged at 17,000rpm for 
30min at 4°C. The supernatant of the sample was mixed with the glutathione-sepharose beads (GE 
healthcare) for 4hours at 4°C. The beads attached with GST tag recombinant proteins were washed 
with the washing buffer (50mM Tris-HCl, pH 7.4, 500mM NaCl, 5mM MgCl2). For cleavage of GST-
tagged protein bound to glutathione-sepharose, the 80unit of thrombin was treated in 1ml bead sample 
overnight at 4°C. Lastly the thrombin was removed by pAmino benzamidine-Agarose. 
 
His tagged CypD protein purification: The CypD fused to His-tag (pET28b) were overexpressed 
from Escherichia coli BL21/DE3 cells grown in Luria Broth (LB) medium in presence of ampicillin 
at 36°C. When thehe cell reached OD600 0.4-0.6, the recombinant protein was induced by addition of 
isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.1mM for 24hr at 18°C. The 
bacterial cell was harvested by centrifugation at 3,500rpm for 15min at 4°C. The harvested cell was 
resuspended in lysis buffer (50mM NaH2PO4, 300mM NaCl, 20mM Imidazole) with final 
concentration of 1mM DTT or 5mM β-mercaptoethanol. The resuspended bacteria sample in the ice 
was burst by using ultra-sonicator. The lysis sample was centrifuged at 17,000rpm for 30min at 4°C. 
The supernatant of sample was applied in Ni-NTA bead charged in open column (Quiagen) and 
allowed to enter the resin by gravity flow at 4°C. The beads attached with His tag recombinant 
proteins were washed with the washing buffer (50mM NaH2PO4, 300mM NaCl, 50mM Imidazole). 
The elution buffer 50mM NaH2PO4, 300mM NaCl, and 250mM Imidazole) was added in column and 
allow it to elute the proteins by gravity flow. The protein sample diluted at 15 times by the buffer 
(50mM NaH2PO4, 300mM NaCl) was re-loaded on HI-TRAP HP column (GE Healthcare) and it was 
further purified by FPLC. 
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I-2-4. Pull down assay 
 
The screening of CypD binding partner proteins: The same amount of six His tag only protein and six 
His fusion protein bound with Ni-NTA beads were loaded to mouse (Balb/c, 5weeks) brain 
mitochondria extract for overnight at 4°C. The reaction mixture was washed with Hepes lysis buffer 
(20mM Hepes, 75mM Kcl, 0.1 mM EDTA, 2.5mM Mgcl2, 0.5% Triton-X, 0.05% Nonidet P-40, pH 
7.7) containing protease inhibitors cocktail. The samples were boiled with SDS loading dye, and 
analyzed by immunoblotting and coomasie-staing.  
 
In vitro binding test: The same amount of GST tag only protein and GST tag fusion protein bound 
with glutathione-sepharose beads were mixed with recombinant proteins for overnight at 4°C. The 
reaction was performed in binding buffer (Tris-cl pH8.0, 50mM Nacl). The reaction mixtures were 
washed with buffer (Tris-cl pH8.0, 50mM Nacl). The samples were boiled with SDS loading dye, and 
analyzed by immunoblotting and coomasie-staining.  
 
I-2-5. Thrombin removal with pAmino benzamidine-Agarose 
 
50unit of thrombin were removed by rotating at 4°C for 4hr with pAmino benzamidine-Agarose 
(Sigma) 100ul. Before using the pAmino benzamidine-Agarose, it was washed with water 2 times, 
and finally buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 5mM MgCl2). 
 
I-2-6. Mitochondria isolation from Brain 
 
The fresh tissues from mouse (Balb/c, 5weeks) were chilled on ice. The tissue was washed twice with 
extraction buffer (20mM Hepes, 400mM mannitol, 140mM sucrose, 2 mM EGTA, pH7.5). The 
tissues were cut into small pieces with a pair of scissors. The chopped tissues were mixed with buffer 
(20mM Hepes, 400mM mannitol, 140mM sucrose, 2 mM EGTA, pH7.5) and homogenized using a 
homogenizer. Homogenates of tissues were centrifuged at 1000×g for 5min at 4°C. Following 
centrifugation, lipid was carefully removed, and the remaining supernatant was centrifuged again at 
1000×g for 5min at 4°C. The pellet was re-suspended and centrifuged at 11,000×g for 10min at 4°C. 
The final pellet was stored at -80°C or re-suspended in a Hepes lysis buffer (20mM Hepes, 75mM Kcl, 
0.1 mM EDTA and 2.5mM Mgcl2, 0.5% Triton-X, 0.05% Nonidet P-40, pH 7.7) for direct using. 
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I-2-7. Cell culture  
 
MDA-MB-231 and H9C2 cell lines were grown in DMEM (Lonza) medium supplemented with 10% 
feral bovine serum (Lonza), 1% antibiotics (streptomycin/penicillin), and maintained at 37 °C in a 5% 
CO2 incubator.  
 
I-2-8. Cell staining using Mitotracker and TMRM 
 
The working concentration of Mitotracker and TMRM was 300nM. Mitotracker (Invitrogen) and 
TMRM were mixed with media and treated it to the cell. The cell was incubated in the cell culture 
incubator for 30min. After the 30min for staining, the dye contained media was replaced as fresh 
media. The storing of Mitotracker and TMRM was in the DMSO and methanol at -20°. The excitation 
and emission value of mitotracker and TMRM is 644 / 665 and 543 / 585. 
 
I-2-9. Immunoblotting 
 
CypD antibody (Calbiochem: AP1035), PrxIII (Santacruz: sc-59661), PrxV (Abcam: ab16751) and 
secondary antibody (KPL: 074-1506) have been used. The primary antibodies were stored in primary 
antibody solution (TBS-T with 0.02% sodium azaide, 1mg/ml BSA), -20°C. The PVDF membranes 
transferred from SDS-PAGE gel were incubated with primary antibodies at 4°C for 12hr. The reacted 
membranes were washed with TBS-T (50mM Tris, 150mM NaCl, Tween-20 0.05%, pH7.4) and re-
incubated with secondary antibody at 25°C for 1hr. 
 
I-2-10. FPLC 
 
CypD: The buffer A is 50mM MES pH6.5 and the buffer B is 50mM MES pH6.5, NaCl 1M. Using 
HiTrap Q Desalting column (GE Healthcare), the buffer which the CypD was stored (50mM Tris-HCl, 
pH 7.4, 500mM NaCl, and 5mM MgCl2) was changed to the buffer A. If the volume of protein was 
too much to run the FPLC, Amicon Ultra-4 centrifugal filter (Millipore) was used. The CypD stored 
with buffer A was loaded to HiTrap SP HP cation exchange chromatography column (GE health care) 
using FPLC (AkTa FPLC, GE health care). The buffer of purified protein was changed to storing 
buffer (Tris-Cl pH8.0, NaCl 50mM). At each step, the centrifugation, 13,000rpm for 10min, was 
needed to remove aggregate of samples. 
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PrxV: The buffer A is 10mM Tris pH8.0 and the buffer B is 10mM Tris pH8.0, NaCl 1M. Using 
HiTrap Q Desalting column (GE Healthcare), the buffer which the PrxV was stored (50mM Tris-HCl, 
pH 7.4, 500mM NaCl, and 5mM MgCl2) was change to Tris buffer A. If the volume of protein was 
too much to run the FPLC, Amicon Ultra-4 centrifugal filter (Millipore) was used. The PrxV stored 
with buffer A was loaded to HiTrap Q anion exchange chromatography column (GE health care) 
using FPLC (AkTa FPLC, GE health care). At each step, the centrifugation, 13,000rpm, was needed 
to remove aggregate. PrxV was purified at the peak of non-binding protein. 
 
I-2-11. Isothermal Titration Calorimetry (ITC) 
 
The reaction buffer was Tris buffer pH8.0, 50mM NaCl. CypD(30ug/ul)was in the syringe and 
PrxV(3ug/ul) was in the cell on the ITC(GE Healthcare). The reaction of PrxV with Hydrogen 
peroxide (50uM) was incubated for overnight at 4°C. The reaction condition of ITC was at room 
temperature. 
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Table 1. Schematic representation of six mammalian Prx families. 
The diverse type of Prxs family has the reactive Cys and conserved Cys except PrxVI which are not exactly 
known, yet. The locations of Prxs are located in cytosol, membrane, peroxisome and mitochondria. The number 
of functional subunit of Prxs is monomer or dimer, but the diverse binding formation can exist according to the 
environmental conditions. To recycle the oxidized Prxs, the electron donors are required. The PrxIII/IV/V have 
the targeting sequence in front of their major sequence. 
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Figure 1. Catalytic cycle of the mitochondrial Prxs 
PrxIII has two subunit peptides and they meet reverse like reflected mirror image. Because of that, the reactive 
Cys on the one peptide meet the conserved Cys on another peptide. The cycle of recycling is same as other Prxs, 
but when PrxIIIs are over exposed against ROS, they are over oxidized which are difficult to be recycled. For 
reducing their formation, the sulfiredoxin from the cytosol is transferred to mitochondria. The mechanism of 
transfer of surfiredoxin is not known exactly, yet. In case of PrxV, the one peptide composes it. Because of that, 
the oxidation of reactive Cys is reduced by itself through banding of its peptide. 
 
 
A 
B 
- 18 - 
 
 
 
 
 
Figure 1-2. The peroxidase recycling reaction of PrxIII. 
When the reactive Cys meet the ROS, it changes their formation to oxidation and makes hydrogen monoxide. 
The conserved Cys is involved in reducing the oxidation form of reactive Cys. After reaction between the 
reactive Cys and conserved Cys, it makes di-sulfide link between those two Cys. The di-sulfide bond is reduced 
by electron donor like thioredoxin or glutathione which are different according to the type of Prxs. For 
recharging the electron donors, the thiordoxin reductase or glutathione reductase which gets the electron from 
the NADPH transfer an electron to them. 
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I-3. Results  
 
I-3-1. The preparation of screening. 
 
The CypD binding proteins are screened by pull down assay using six His tagged CypD attached 
with Ni-NTA agarose bead and brain mitochondria. For preparing the mitochondria extract as input 
sample, the brain of Balb/c, 5weeks, Female mouse are used. The reasons of using the brain are that it 
is sensitive against ROS generation, tightly regulated by diverse antioxidants and the contamination 
rate of blood is lower than other organs. The mitochondria from the brain of mouse was dissolved 
using HEPES buffer and broken using a 31 gauge insulin injection syringe and the supernatant are 
mixed with purified CypD. The recombinant CypD construct does not have not the mitochondrial 
targeting sequence as the mitochondrial targeting sequence is deleted when the CypD arrive at 
mitochondria. For preparation of six His tagged CypD, pET-28b (+) CypD vector was transformed to 
BL21/DE3 E. coli and cultured at 18°C, for 24hr. The overexpression of CypD in bacterial system 
was fine and it was stably expressed in solution (Figure 2A). The bacterial extract involved in CypD 
was loaded to Hi-TRAP Chelating HP column and purified by FPLC (Figure 2B).  
 
 
 
 
Figure 2. The recombinant CypD purification 
The activation form of CypD was overexpressed in BL21/DE3 E. coli. The addition of IPTG induced the over 
expression of CypD in bacterial system (Lane 2). The solubility of CypD was stabled in solution (Lane 4) (a). 
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The bacterial extract was mixed with Ni-NTA agarose bead in the open column. It was eluted by 250mM 
Immidazole and rebound to Hi-TRAPTM Chelating HP column. The amount of imidazole for eluting the CypD 
was loaded as linear gradient. The highly qualified recombinant CypD was eluted at 150mM Immidazole (b).  
Overexpression condition: O.D.(600)0.4~0.6, IPTG 0.2mM, 18℃, 24h. 
★: The peak of recombinant CypD. 
 
 
I-3-2. Screening of CypD partner proteins. 
 
The purified recombinant CypD was rebound to Ni-NTA agarose bead and incubated with 
mitochondria extracts for 12hr. The reaction samples were poured in to the open column and 
nonbinding proteins were eluted. In case of nonbinding fraction samples, the positive protein bands 
appeared at the control sample and not at the CypD mixed sample (Figure 3A). On the other hand, the 
positive protein bands of the binding fraction samples which eluted using 10M urea were on the CypD 
mixed sample and not on the control sample. The positive bands were analyzed through MALD-TOF. 
From the results of MALD-TOF MS, ANT and Hsp90 already known as the partner of CypD and 
novel one, PrxV were founded (Figure 3B).  
 
 
 
Figure 3. Screening of CypD-binding protein. 
The purified recombinant CypD was rebound with Ni-NTA agarose bead and incubated with mitochondria 
extract 1ml (1mg/ml). The fractions of samples were loaded on SDS-Page gel and stained with coomasie blue. 
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Ni-NTA bead was loaded as control of CypD binding Ni-NTA bead. The band of proteins not on the CypD bead 
sample line but on the empty bead fraction line were positive bands of nonbinding fraction lines. In case of 
binding fraction, protein bands of candidates were only on the CypD bead sample line (A). The PrxV was found 
on the isolated protein bands which is checked as the star and analyzed through the MALD- TOF MS. The 
proteins in a box of diagonal line have the low number of similar peptide sequence and others have high score of 
peptide sequence coverage (B).Though the transcriptional enhancer factor, TEF-5, has a high score, it was not 
selected due to the localization of protein.  
 
 
 
 
 
Table 2. The PrxV protein sequence coverage: 42% 
The peptide sequence show the similarity of mouse derived PrxV with MALD- TOF analysis results. 
* The matched peptides are in boxes using bold letter. 
 PE: Protein existence. 
 SV: Sequence version. 
 
 
I-3-3. The PrxIII has the possibility of binding with CypD. 
 
In mitochondria, not only the PrxV is the candidate of CypD partner protein but also the PrxIII exists. 
As they are involved in the family of Prxs, they might have the similar conserved sequence. For this 
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reason, I compared the peptide sequence and aligned the secondary structure of them. The peptide 
sequence is quite different between PrxV and Prx III (Figure 4A). But the portions of the similar 
sites exists and the secondary structures of the central active Cys group are very similar (Figure 4B).  
 
 
Figure 4. The alignment of the mitochondrial Prxs 
As the PrxIII also exists in the mitochondria, I compared the peptide sequence of PrxIII and PrxV to estimate 
the possibility of binding with CypD. Through the alignment data, the core peptide portion of PrxIII and PrxV 
show a small rate of sequential similarity (A), but the secondary structures there are very similar (B). 
* Red bar: Alpha helix, Yellow bar: Beta sheet structure (B). 
 
 
I-3-4. In vitro pull down assay of CypD - PrxIII and PrxV. 
 
As the PrxIII and PrxV have same functional ability and similar second structures, PrxIII may bind 
with CypD, too. Therefore, the capability of binding with CypD was confirmed through the in vitro 
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pull down assay. The genes of PrxIII and PrxV were extracted from MDA-MB-231, human breast 
cancer cell line and inserted in pGEX-4T1, GST expression vectors (Figure 5A). As the wild type 
PrxIII and PrxV have the mitochondrial targeting sequence, the forward primer of PrxIII and PrxV 
were designed next to the targeting sequence (Figure 5B).  
 
 
 
 
Figure 5. The cloning of PrxIII and PrxV into GST expression pGEX-4T1 vector. 
The gene of PrxIII and PrxV are derived from breast cancer cell line, MDA-MB-231. Because of the 
mitochondrial targeting sequence’s deletion, the size of mitochondrial PrxIII and PrxV are smaller than wild 
type of PrxIII and PrxV.  
 
 
Recombinant proteins were overexpressed in BL21/DE3 E. coli cells. Expressed proteins were 
purified using glutathione-sepharose beads. After preparation of protein binding bead samples (Figure 
6A), the thrombin was treated to get the input proteins. The thrombin mixed with bead samples were 
removed through treating the pAmino benzamidine-Agarose (100ul / 50unit thrombin), 4℃ for 4hr. 
When the purified CypD sample was mixed with the small amount of PrxIII binding bead, the CypD 
clearly bound to PrxIII and not bound to GST control bead (Figure 6B). Reversely, when the purified 
PrxIII protein was mixed with CypD binding bead, the binding of two proteins was confirmed (Figure 
6C). In case of PrxV, it bound CypD binding bead, as well (Figure 6D).  
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Figure 6. GST pull down assay in vitro. 
Glutathione-sepharose beads were coupled with GST or GST-PrxIII / V / CypD fusion recombinant proteins. 
The input protein samples were got from the thrombin treated protein binding beads (A). The CypD protein 
(20ug) was incubated with PrxIII binding bead (B). The PrxIII protein (20ug) was mixed with CypD binding 
bead (C). The PrxV protein (20ug) was incubated with CypD proteins (D). The results were analyzed by 
immunoblotting. The results of coomasie staining show that the same amount of the GST and target protein 
binding beads are loaded. (mCypD: 18Kda, mPrxIII: 24Kda, mPrxV: 17Kda) 
 
Instead of using recombinant proteins at pull down assay, the mitochondrial extracts of mouse brain 
(Balb/c, 5weeks) were used. The recombinant CypD binding bead was added to mitochondrial 
extracts and mixed for overnight at 4℃. The binding of recombinant CypD with PrxIII and PrxV was 
confirmed through the immunoblotting results (Figure 7A, B). 
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Figure 7. The pull down assay using mitochondrial extracts with CypD binding glutathione-sepharose 
beads. 
The mitochondria were extracted from mouse (Balb/c, 5weeks) and the CypD binding sepharose bead (1ul, bed 
volume) was mixed with mitochondrial extracts(1ml, 1ug/ul) for overnight at 4℃. PrxIII (A) and PrxV (B) 
results were got from same membrane. The coomassie results under the immunoblotting results confirmed the 
same amount of GST control bead and recombinant protein binding bead were loaded. 
 
 
I-3-5. Purification of proteins using FPLC 
 
Isothermal titration calorimetry (ITC) which confirms the binding capacity through measuring the 
changing of thermo dynamics was needed to verify the interactions between CypD and PrxV on 
diverse conditions. First of all, the preparations of highly purified proteins were required. The storing 
buffer of CypD and PrxV, purified by GST affinity chromatography were changed using HiTrap 
desaliting column and more purified through ion exchange chromatography. The storing buffer of 
CypD was changed to MES pH6.5 buffer and it was loaded to SP HP cation ion exchange column 
(Figure 8A). The characters of CypD, which easily aggregated on acidic conditions and get weak 
ionic charges on alkali conditions, make hard to decide the ion exchange condition. The CypD in the 
MES pH6.5 buffer showed minimium the aggregation and fine binding capacity with cation ion 
exchange chromatography resins. Finally, the purified CypD was stored at Tris pH8.0 with NaCl 
50mM buffer. PrxV pre-purified through GST affinity chromatography was lastly purified using 
MonoQ anion exchange chromatography column. The best condition to get the highly purified PrxV 
was the unbounded protein state using the MonoQ anion exchange chromatography column with the 
buffer, Tris pH8.0, NaCl 50mM. The storing buffer of PrxV was Tris pH 8.0 with NaCl 50mM same 
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as CypD storing buffer (Figure 8B). As the dithiothreitol (DTT) has influence on the ITC results, the 
reducing agent for purifying those proteins was beta-mercaptoethanol not DTT. 
 
 
 
 
 
Figure 8.  Expression and purification of recombinant protein. 
The recombinant proteins primary purified using glutathione-sepharose beads were secondararily purified 
through ion exchange chromatography. The buffer of CypD was changed to MES pH6.5, NaCl 50mM for cation 
exchange chromatography. The buffer changed CypD was loaded to SP HP column and eluted by linear 
gradients of NaCl. The CypD was eluted at 300mM Nacl and stored at Tris pH8.0, NaCl 50mM (A). The buffer 
of PrxV was changed to Tris pH8.0, NaCl 50mM and loaded to MonoQ anion exchange column. As the PrxV 
uncoupled with MonoQ resin, at pH8.0, it was eluted at first (B). The other peaks in linear gradient range of 
MonoQ anion exchange column are non-specific binding proteins. The coomasie staining result shows the 
purified proteins (A).  
 
 
I-3-6. Isothermal Titration Calorimetry (ITC) 
 
The purified CypD and PrxV were prepared at 30ug/ul (1.33M) and 3ug/ul (0.176M) for ITC. As I 
thought that the changing of oxidation level by hydrogen peroxide affect the binding capacity of 
PrxV against CypD, 200uM and 500uM of hydrogen peroxide was mixed with PrxV and incubated 
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for 30min at 4℃. After incubation, the CypD was inserted in the syringe and PrxV was loaded in the 
cell of ITC. Interestingly, the binding of CypD with PrxV was confirmed (Figure 9A), but the 
samples mixed with hydrogen peroxide show the unstable bindings (Figure 9B, C).  
 
 
 
 Figure 9. ITC for measuring the binding capacity of CypD and PrxV 
The purified CypD (30ug/ul) was injected in the syringe and PrxV (3ug/ul) was loaded in the cell of ITC. After 
reaction, the Kd value of CypD with PrxV was 3.5uM (A) while the Kd value of CypD with PrxV which reacted 
with hydrogen peroxide, 200uM and 500uM for 30min at 4 ℃ was 18.9uM and 44.6uM (B, C).  
 
 
I-3-7. Surface plasmon resonance (SPR) 
 
I confirmed the binding of CypD with PrxV through the pull down assay and ITC. Interestingly, 
hydrogen peroxide affect to the interaction of CypD and PrxV. This aspect was appeared in SPR 
(Biacore 3000) using CM5 chip. Flow cell 1(FC1) was negative control (without any proteins), while 
PrxV was immobilized in the experimental flow cell (FC2). The value of Rmax was 7000RU. 1mM 
DTT was used as reducing agent for cutting the double sulfide bond of PrxV for 30min, 1ul/min at 25℃ 
and CypD was flowed in different concentrations at 25℃, 60ul/min (Figure 10A). The regeneration 
step was washed with 20mM NaOH. Results, measured as response unit (RU) were obtained with 
change of sensorgrams from FC2 compared with FC1. In case of hydrogen peroxide, it was flowed on 
the cell instead of 1mM DTT (Figure 10B). The interaction pattern of PrxV with CypD was appeared 
in SPR, but the KD value of reduced condition was lower than the oxidative condition. The similar 
result was shown at ITC, interestingly. The KD values compared with ITC and SPR were different. 
Perhaps, the difference of reaction buffer and the status of PrxV according to the experimental method 
(Solution method: ITC / Binding method: SPR) cause it. 
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Figure 10. High resolution kinetics analysis of the binding of CypD to PrxV surface using Biacore 
3000 biosensor.  
FC1 was negative control (without any proteins), while PrxV was immobilized on the FC2. The value of Rmax 
was 7000RU and reaction flow rate was 60ul/min at 25℃. CypD samples were prepared by serial dilutions in 
reaction buffer, HBS-N. CypD binding data were fit to a 1:1 interaction model, A+B = AB. 1mM DTT (A) and 
200uM H2O2 (B) were used as reducing agent and oxidizing agent of PrxV. KD(Dissociation constant) = kd / ka 
(C). 
 
- 29 - 
 
I-3-8. The knockdown of PrxV affect to the mitochondrial membrane potential 
 
If the function of CypD is affected by PrxV through the direct binding, the maintenance of the PrxV 
may be important to regulate the mitochondrial membrane potential. The constructs of small 
interference RNA (siRNA) were treated to H9C2 cell for 48 hours and co-stained with Mitotracker 
and Tetramethyl Rhodamine Methyl Ester (TMRM). The Mitotracker was used to control of TMRM 
stained mitochondria. At normal condition, the TMRM is stably stored in mitochondria, but if the 
mitochondrial permeability transition pores are opened, TMRM is released to cytosol through the pore. 
Through the confocal microscopy, it was confirmed that the membrane potential of PrxV knockdown 
cell was decreased (Figure 10A, B and C). After the treatment of hydrogen peroxide (50uM) for 
15min, the decreasing rate of the membrane potential of PrxV knockdown H9C2 cell was faster than 
negative control cell line. The scale of mitochondrial TMRM was averaged using the selected regions 
of interest (ROI) and showed it in a graph (Figure 10D). Through the FACS data, the knock down of 
PrxV was not affect to the level of mitochondrial ROS.  
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Figure 11. The PrxV knockdown affect to mitochondrial membrane potential 
The fluorescence of TMRM stained mitochondria was checked using PrxV knockdown H9C2 cell line. The 
siRNA was treating for 48hr. The mitotracker (300nM) was co-stained with TMRM as the control of TMRM. 
The TMRM fluorescence of PrxV knockdown cell (B, C) was weake than siControl treated H9C2 cell (A). The 
ROI designated cell number was one hundred cells per sample and the selected points were one point of region 
per cell. The ROI value of the fluorescence regions were adjusted using ROI value of the dark spaces. The P 
value of ROI’s average was under the 0.05 (D). The decreasing level of PrxV by treating siPrxV-1 and siPrxV-2 
was confirmed by immunoblotting (E). The PrxV knock downed H9C2 cell was stained with Mito-Sox for 
30min and analyzed through the FACS.  
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I-4. Discussion 
 
The mitochondrial outer membrane (OM) permeabilization leads to apoptotic protein release 
(Garrido et al., 2006; Green & Reed, 1998; Kroemer et al., 2007; Tsujimoto & Shimizu, 2007). The 
opening of the PT pore allows an influx of ions and water into mitochondrial matrix, inducing 
mitochondrial swelling (Henry-Mowatt, Dive, Martinou, & James, 2004). These reactions trigger the 
burst of mitochondrial outer membrane and the release of inter-membrane space (IM) proteins. The 
core proteins of permeability transition pore complex are a voltage-dependent anion channel (VDAC), 
adenine nucleotide translocase (ANT), and Cyclophilin D (CypD) (Schinzel et al., 2005). Other 
proteins, peripheral benzodiazepine receptor (PBR), hexokinase (HK), and creatine kinase (CK) are 
already known as the member of MPTPC (Song et al., 2011).The triggers of making MPTPC are the 
density of calcium, cell death signals and ROS, etc. 
 In mitochondria, ROS naturally generated by respiration is very tightly regulated by antioxidant as 
the defense mechanism. The PrxV is the one of the antioxidents in mitochondria and peroxisome in 
cytosol. In this study, PrxV were identified to associate with of CypD using MALDI TOF MS 
spectrometry analysis. In addition, PrxIII also exists in mitochondria and have same function against 
ROS generation. Interestingly, both of the PrxIII and PrxV bind to CypD in vitro system. The Prxs 
change their formation by oxidation and they can make diverse oligomeric conformations. On the 
basis of these studies, the binding capacity of mitochondrial Prxs against CypD may be different 
according to the ROS environment. Through the ITC, I confirm that the binding capacity of PrxV 
with CypD was increased on the status of oxidation environment. These results present the possibility 
of ROS dependent CypD modulator. For confirming the functions of mitochondrial Prxs, I designed 
siRNAs and decrease the mitochondrial membrane potential, dramatically. The point is that the reason 
of the decreasing membrane potential is not caused by ROS. It was confirmed by FACS data and I 
thought that the compensation effects against knock down of PrxV are arisen. In tumors, it is already 
known that the ROS level is higher than normal cell and the some types of tumors have the larger 
amount of PrxIII and V. I thought that the CypD is adequately inhibited by mitochondrial Prxs in 
normal cell condition. However, in tumors, the over-expressed Prxs authorizes tumor cells to resist 
high level of ROS condition by excessively inhibiting CypD. If the excessive ROS generation that 
was enough to oxidize PrxV are induced by anti-cancer drugs, PrxV dissociate itself from CypD for 
leading apoptosis (Figure 12). 
Structural and functional transitions of mitochondria are associated with malignancy in much type of 
tumors. From these studies, as I assumed that the mitochondrial Prxs inhibit the CypD functions that 
make MPTPC and the development of mitochondrial Prxs targeted drugs can make synergetic effects 
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through the combinational drug treatment which induce mitochondrial dependent cell death. 
 
 
 
 
Figure 12. A Model Illustrating the Mechanism between CypD and PrxV. 
As PrxV normally inhibit the CypD through direct but reversible binding, the MPTP is stably regulated. If the 
massive ROS generation is induced, PrxV is oxidized and it changes their conformation. The conformational 
change induces detachment of PrxV from CypD. The unlocked CypD get the more chance to make MPTP 
complex. In many cases, the diverse type of tumors overexpresses mitochondrial Prxs and generates high level 
of ROS in mitochondria. Even if the tumors are on the high level of ROS status, the MPTP opening is not 
induced. I suppose that the one of the mechanisms to resist high level of ROS condition in tumors is by 
overexpressing PrxV. 
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